Mendus

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry and investor conferences in September:

International Society for Cell & Gene Therapy Europe 2024 Regional Meeting
Gothenburg, Sweden, September 4-6, 2024
Mendus will present the regulatory milestones of its clinical-stage programs vididencel and ilixadencel during a poster session held on September 4, 18.30–20.00 CEST. In addition, Mendus Head of Regulatory Affairs, Dr Anna Koptina Gültekin, will participate in a panel discussion held on September 5 about the importance of interactions with regulatory authorities during drug development.
ISCT EU 2024

H.C. Wainwright 26th Annual Global Investment Conference
New York City, USA, September 9-11
Mendus CEO Erik Manting will participate for investor meetings and a company presentation.
HCW Events

Nordic Life Science Days 2024
Malmö, Sweden, September 18-19, 2024
Mendus CEO Erik Manting will take part in a presentation hosted by the Dutch Government about the collaboration potential between Sweden and The Netherlands in the Life Sciences sector.
NLSDays

Pareto Securities' 15th Annual Healthcare Conference
Stockholm, Sweden, September 19, 2024
Mendus CEO Erik Manting will participate for investor meetings and a company presentation.
Pareto Securities' 15th Annual Healthcare Conference